Abstract
We determined the pharmacologic profile of ASP7657, trans-4-[({[1-(quinolin-2-ylmethyl)-5-(trifluoromethyl)-1H-indol-7 yl] carbonyl} amino) methyl] cyclohexanecarboxylic acid methanesulfonate (1:1), a newly synthesized selective E-type prostaglandin (EP)4 receptor antagonist using several in vitro and in vivo experiments. ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively. In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively. In contrast, ASP7657 did not inhibit the PGE2-induced intracellular calcium increase in HEK293 cells expressing rat EP1 and EP3 receptors, or cAMP increase in CHO cells expressing rat EP2 receptors. ASP7657 showed good pharmacokinetic properties following oral dosing and dose-dependently antagonized the prostaglandin (PG)E2-mediated inhibition of lipopolysaccharide-induced tumor necrosis factor-α release from rat whole blood culture. In addition, 4 weeks repeated oral administration of ASP7657 dose-dependently attenuated albuminuria in type 2 diabetic mice; these effects were significant at doses of 0.01 mg/kg or higher. These results demonstrate that ASP7657 is a potent and selective EP4 receptor antagonist that may be useful in future studies to help clarify the physiological and pathophysiological roles of PG.
Similar content being viewed by others
References
Akmal M (2001) Hemodialysis in diabetic patients. Am J Kidney Dis 38:S195–S199
Breyer MD, Jacobson HR, Breyer RM (1996) Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 7:8–17
Fioretto P, Dodson PM, Ziegler D, Rosenson RS (2010) Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 6:19–25
Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins AJ (2005) Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16:3736–3741
Hall PM (2006) Prevention of progression in diabetic nephropathy. Diabetes Spectr 19:18–24
Jensen BL, Schmid C, Kurtz A (1996) Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Phys 271:F659–F669
Mohamed R, Jayakumar C, Ramesh G (2013) Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6. Lab Investig 93:933–945
Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193–1226
Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69:1511–1517
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P (2001) Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878
Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P (2005) Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54:2206–2211
Purdy KE, Arendshorst WJ (2000) EP1 and EP4 receptors mediate prostaglandin E2 actions in the microcirculation of rat kidney. Am J Phys 279:F755–F764
Sharma K, McCue P, Dunn SR (2003) Diabetic kidney disease in the db/db mouse. Am J Phys 284:F1138–F1144
Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4–14
Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CR (2010) A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 21:1678–1690
Thieme K, Majumder S, Brijmohan AS, Batchu SN, Bowskill BB, Alghamdi TA, Advani SL, Kabir MG, Liu Y, Advani A (2017) EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep 7:3442
Wall EA, Zavzavadjian JR, Chang MS, Randhawa B, Zhu X, Hsueh RC, Liu J, Driver A, Bao XR, Sternweis PC, Simon MI, Fraser ID (2009) Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signal 16:ra28
Yang GX, Xu YY, Fan YP, Wang J, Chen XL, Zhang YD, Wu JH (2014) A maladaptive role for EP4 receptors in mouse mesangial cells. PLoS One 9:e104091
Acknowledgments
The authors thank Drs. Akiyoshi Shimaya, Yuichi Tomura, and Atsuo Tahara (Astellas Pharma Inc.) for their valuable comments and continuing encouragement.
Author information
Authors and Affiliations
Contributions
KM, HK, HY, II, EN, KW, and TU conceived and designed the research. KM, HK, HY, II, and TU performed experiments and analyzed the data. EN contributed to the synthesis of ASP7657. KM and KW wrote the manuscript. All authors read and approved the manuscript.
Corresponding author
Ethics declarations
Animal studies were approved by the Institutional Animal Care and Use Committee of Astellas Pharma Inc., Tsukuba Research Center, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Mizukami, K., Kamada, H., Yoshida, H. et al. Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Naunyn-Schmiedeberg's Arch Pharmacol 391, 1319–1326 (2018). https://doi.org/10.1007/s00210-018-1545-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-018-1545-x